London, UK (PRWEB) December 23, 2011
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia.
The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
New market research study “Acute Myeloid Leukemia Therapeutics Market (2010 - 2020) (Pipeline Assessment & Market Forecast in G8 Countries)” elaborated by MarketsandMarkets has been recently published by Market Publishers Ltd.
Title: Acute Myeloid Leukemia Therapeutics Market (2010 - 2020) (Pipeline Assessment & Market Forecast in G8 Countries)
Published: December, 2011
Price: US$ 4,650
The report studies the market from 2010 to 2020 covering seven major regimens and single drugs (off-patent and pipeline) for acute myeloid leukemia treatment. It features an in-depth examination of the market metrics, market players, developments and the future of the market.
The report evaluates the therapeutics market of acute myeloid leukemia in G8 countries with respect to the current and pipeline drugs and regimens. It analyzes geography; forecasting revenue, and trends in each of the following submarkets:
- Chemotherapy regimens
o DC regimen
o AVD Regimen
o VCD regimen
- Chemotherapy drugs
- Pipeline drugs
The geographies examined by the report are
- North America
Information on market data, drivers, trends and opportunities, key players, and competitive outlook can be found in each section. The study also features market tables covering the sub-segments and micro-markets.
More new market research reports by the publisher can be found at MarketsandMarkets page.